Nuvalent (NUVL)
(Delayed Data from NSDQ)
$74.11 USD
+1.95 (2.70%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $74.12 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Nuvalent, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NUVL 74.11 +1.95(2.70%)
Will NUVL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Sep 17, 2024
Other News for NUVL
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight
Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)
Nuvalent Inc Reports Q2 2025 EPS of -$1.39, Missing Estimates; Net Loss Reaches $99.7 Million
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, ...
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc